Genmab A/S (GMAB) Competitors & Peers
The 5 largest companies in the same industry as Genmab A/S, by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| VRTX | Peer | $526.19 | P/E 30.6RSI 53Cap 133.1 B |
| REGN | Peer | $788.04 | P/E 19.9RSI 54Cap 82.8 B |
| ARGX | Peer | $959.49 | P/E 36.2RSI 42Cap 59.4 B |
| RVMD | Peer | $204.97 | RSI 41Cap 41.4 B |
| ALNY | Peer | $255.96 | P/E 43.3RSI 51Cap 33.2 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- JNJPartner
Genmab + JNJ co-developed Darzalex (daratumumab); royalty stream to Genmab.
Model-inferred, unverified — treat as a lead, not evidence - DSNKYCompetitor
ADC pipeline overlap.
Model-inferred, unverified — treat as a lead, not evidence